ESTRO PT 2018

BRE008-12 Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node Irradiation

BREAST CONSERVING THERAPY: Whole breast and regional lymph nodes (axilla levels I-III, supraclavicular*): 45 - 50.4 Gy (RBE) in 25 - 28 fractions of 1.8 Gy (RBE) per fraction and Internal mammary node chain (IMC) for stage III patients*: 45 - 50.4 Gy (RBE) in 25 - 28 fractions of 1.8 Gy (RBE). + Lumpectomy tumor bed boost to a total cumulative dose of 61.2 - 66.6 Gy (RBE) in 1.8 Gy (RBE) per fraction ENDPOINTS: Reduction of incidence of major cardiac morbidity Maintaining comparable Local control and Survival at 5 years Cosmesis Quality of Life MASTECTOMY: Chest wall and regional lymph nodes (axilla levels I-III, supraclavicular*): 45 -50.4 Gy (RBE) in 25 - 28 fractions of 1.8 Gy (RBE). and Internal mammary node chain (IMC), for stage III patients*: 45 - 50.4 Gy (RBE) in 25 - 28 fractions of 1.8 Gy (RBE). + Chest wall scar boost (optional): for a total cumulative dose of 61.2 Gy (RBE) in 1.8 Gy (RBE) per fraction.

R

E

G

I

S

T

E

R

PI’s: E. Hug, M. Fagundes, M. Pankuch, N. Schreuder et al. – opened 2/2013.

27